Nihar Umesh Shah, MD
Gastroenterology · Berkeley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
Offices
5 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Shah’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A133210 · Current
Licensed to practise in California · since 2014 · expires 2026-11-30 · Maharashtra University of Health Sciences, Nashik, Terna Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$64,013
Medicare paid this office $64,013 for 312 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (45+ min) | 111 | $15,583 | $140 |
| Return visit (30+ min) | 84 | $11,725 | $113 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 40 | $9,581 | $234 |
| Short return visit (20+ min) | 37 | $3,982 | $85 |
| Biopsy of large bowel using a flexible endoscope | 34 | $3,454 | $102 |
See all 9 services
| New patient visit (45+ min) | 111 | $15,583 | $140 |
| Return visit (30+ min) | 84 | $11,725 | $113 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 40 | $9,581 | $234 |
| Short return visit (20+ min) | 37 | $3,982 | $85 |
| Biopsy of large bowel using a flexible endoscope | 34 | $3,454 | $102 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 29 | $2,881 | $96 |
| New patient visit (30+ min) | 27 | $2,412 | $89 |
| Measurement of liver stiffness | 56 | $1,614 | $29 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,209 | $101 |
Procedures Medicare counted
| Colonoscopy | 38 | More than 58% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 52 | More than 64% of doctors who do this |
Who their Medicare patients are
312 Original Medicare patients in 2024. Average age 73 · Under 65 8% · 85 and older 10% · Women 59% · Also on Medicaid 28% · Health risk score 1.42. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 67% · Chronic kidney disease 28% · Diabetes 27% · Depression 25% · Coronary heart disease 21% · Cancer 17% · Atrial fibrillation 17% · Heart failure 15% · COPD 13% · Dementia 6% · Stroke 6%.
The office billed $449,794, Medicare allowed $83,068 and paid $64,013; for 516 services of 24 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 312 | 516 | 73 | 1.42 | $449,794 | $64,013 |
| 2023 | 296 | 512 | 73 | 1.54 | $411,903 | $60,148 |
| 2022 | 299 | 479 | 73 | 1.26 | $390,354 | $55,233 |
| 2021 | 275 | 460 | 73 | 1.45 | $373,050 | $57,986 |
| 2020 | 184 | 309 | 71 | 1.36 | $249,060 | $36,241 |
| 2019 | 374 | 858 | 67 | 3.33 | $341,831 | $68,310 |
| 2018 | 171 | 331 | 64 | 3.23 | $122,413 | $27,314 |
| 2016 | 44 | 53 | 65 | 2.82 | $11,932 | $3,185 |
| 2015 | 149 | 227 | 61 | 2.49 | $55,999 | $14,959 |
| 2014 | 117 | 157 | 63 | 2.51 | $39,508 | $11,639 |
| 2013 | 51 | 109 | 65 | 2.35 | $22,493 | $7,763 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| New patient visit (45+ min) | 84 | $11,425 | $136 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 35 | $8,716 | $242 |
| Return visit (30+ min) | 67 | $8,258 | $113 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 21 | $3,999 | $190 |
| Short return visit (20+ min) | 41 | $3,862 | $73 |
| Biopsy of large bowel using a flexible endoscope | 31 | $3,824 | $123 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 32 | $3,015 | $91 |
| New patient visit (30+ min) | 33 | $2,725 | $83 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 13 | $2,699 | $208 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,589 | $118 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,938 | $72 |
| Measurement of liver stiffness | 41 | $1,295 | $31 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,229 | $102 |
2022: 13 services
| New patient visit (45+ min) | 78 | $10,456 | $134 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 31 | $7,131 | $230 |
| Return visit (30+ min) | 57 | $6,714 | $103 |
| Biopsy of large bowel using a flexible endoscope | 37 | $4,706 | $127 |
| New patient visit (30+ min) | 51 | $4,600 | $90 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 18 | $3,754 | $209 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 31 | $3,263 | $105 |
| Short return visit (20+ min) | 41 | $2,601 | $60 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 11 | $2,288 | $208 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,444 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,308 | $65 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,172 | $98 |
| Measurement of liver stiffness | 32 | $946 | $30 |
2021: 9 services
| New patient visit (45+ min) | 96 | $14,080 | $147 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 30 | $6,906 | $230 |
| Return visit (30+ min) | 52 | $6,703 | $116 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 21 | $4,425 | $211 |
| New patient visit (30+ min) | 42 | $4,348 | $104 |
| Biopsy of large bowel using a flexible endoscope | 37 | $3,569 | $96 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 32 | $3,041 | $95 |
| Short return visit (20+ min) | 39 | $2,833 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,487 | $65 |
2020: 9 services
| New patient visit (45+ min) | 62 | $8,526 | $138 |
| New patient visit (30+ min) | 38 | $4,010 | $106 |
| Biopsy of large bowel using a flexible endoscope | 27 | $3,937 | $146 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 14 | $3,235 | $216 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 25 | $2,405 | $96 |
| Return visit (30+ min) | 18 | $2,128 | $112 |
| Short return visit (20+ min) | 19 | $1,631 | $63 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,329 | $121 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,019 | $60 |
2019: 10 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 178 | $19,258 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 161 | $19,235 | $56 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 48 | $4,350 | $89 |
| New patient visit (45+ min) | 31 | $4,349 | $140 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 28 | $2,514 | $87 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 16 | $2,359 | $147 |
| Return visit (30+ min) | 23 | $1,916 | $80 |
| Biopsy of large bowel using a flexible endoscope | 21 | $1,544 | $74 |
| Short return visit (20+ min) | 19 | $999 | $53 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 33 | $159 | $4 |
2018: 6 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 79 | $8,368 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 67 | $6,088 | $55 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 19 | $1,843 | $97 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $1,492 | $88 |
| New patient visit (45+ min) | 11 | $1,357 | $123 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 13 | $51 | $4 |
2016: 2 services
| Return visit (30+ min) | 13 | $789 | $61 |
| Short return visit (20+ min) | 11 | $396 | $36 |
2015: 5 services
| Return visit (30+ min) | 62 | $4,567 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $2,928 | $54 |
| Long return visit (40+ min) | 29 | $2,341 | $81 |
| New patient visit (45+ min) | 14 | $1,122 | $80 |
| Short return visit (20+ min) | 12 | $516 | $37 |
2014: 4 services
| Return visit (30+ min) | 33 | $2,518 | $61 |
| Long return visit (40+ min) | 28 | $2,352 | $84 |
| New patient visit (60+ min) | 16 | $2,142 | $134 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,424 | $57 |
2013: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $3,664 | $58 |
| Return visit (30+ min) | 15 | $1,078 | $63 |
Medicaid work
$147 in 2023
Medicaid paid $147 for 64 billed services this clinician did in 2023, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| OFF/OP CNSLTJ NEW/EST MOD 40 | 64 | $147 |
| 2023 | 64 | 1 | 15 | $147 |
| 2019 | 427 | 3 | 34 | $15,503 |
| 2018 | 149 | 3 | 25 | $4,484 |
See the largest Medicaid services in earlier years
2019
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 363 | $11,458 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 25 | $2,955 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 39 | $1,090 |
2018
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 117 | $2,948 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 16 | $1,450 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 16 | $86 |
Drugs they prescribed that Part D paid
$170,208
Pharmacies billed $170,208 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 364) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
288 generic and 76 brand-name prescriptions · $170,208 in drug cost · 19 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rezdiffra | 11 | $45,137 | $4,103 |
| Vemlidy | 12 | $14,843 | $1,237 |
| Ursodiol | 20 | $4,525 | $226 |
| Sod Sulf-Potass Sulf-Mag Sulf | 27 | $1,786 | $66 |
| Azathioprine | 13 | $563 | $43 |
See all 10 drugs
| Rezdiffra | 11 | $45,137 | $4,103 |
| Vemlidy | 12 | $14,843 | $1,237 |
| Ursodiol | 20 | $4,525 | $226 |
| Sod Sulf-Potass Sulf-Mag Sulf | 27 | $1,786 | $66 |
| Azathioprine | 13 | $563 | $43 |
| Gavilyte-G | 42 | $489 | $12 |
| Pantoprazole | 47 | $416 | $9 |
| Omeprazole | 48 | $294 | $6 |
| Peg-3350 and Electrolytes | 13 | $194 | $15 |
| Prednisone | 13 | $28 | $2 |
Year by year
| 2024 | 364 | 164 | 0% (0) | 21% | $170,208 |
| 2023 | 335 | 164 | None | 21% | $269,685 |
| 2022 | 281 | 150 | 0% (0) | 39% | $77,027 |
| 2021 | 275 | 157 | 0% (0) | 49% | $131,048 |
| 2020 | 197 | 108 | 0% (0) | None | $50,903 |
| 2019 | 152 | 62 | 0% (0) | 29% | $38,849 |
| 2018 | 34 | 19 | 0% (0) | 32% | $20,627 |
| 2017 | 17 | None | 0% (0) | None | $76,608 |
| 2016 | 134 | 38 | 0% (0) | 54% | $855,859 |
| 2015 | 183 | 43 | None | 45% | $1,271,208 |
| 2014 | 111 | 26 | None | 42% | $832,383 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Sod Sulf-Potass Sulf-Mag Sulf | 43 | $3,524 | $82 |
| Ursodiol | 11 | $2,665 | $242 |
| Omeprazole | 47 | $897 | $19 |
| Gavilyte-G | 47 | $758 | $16 |
| Pantoprazole | 20 | $554 | $28 |
| Spironolactone | 16 | $235 | $15 |
| Furosemide | 12 | $104 | $9 |
2022: 8 drugs
| Linzess | 16 | $11,607 | $725 |
| Suprep | 30 | $3,420 | $114 |
| Entecavir | 11 | $2,648 | $241 |
| Pantoprazole | 12 | $531 | $44 |
| Gavilyte-G | 29 | $429 | $15 |
| Misoprostol | 16 | $422 | $26 |
| Omeprazole | 39 | $246 | $6 |
| Peg-3350 and Electrolytes | 14 | $185 | $13 |
2021: 5 drugs
| Suprep | 83 | $9,262 | $112 |
| Omeprazole | 46 | $509 | $11 |
| Misoprostol | 13 | $332 | $26 |
| Gavilyte-G | 13 | $159 | $12 |
| Peg-3350 and Electrolytes | 12 | $140 | $12 |
2020: 4 drugs
| Suprep | 25 | $2,607 | $104 |
| Omeprazole | 48 | $393 | $8 |
| Gavilyte-G | 29 | $371 | $13 |
| Pantoprazole | 15 | $213 | $14 |
2019: 5 drugs
| Apriso | 12 | $6,078 | $506 |
| Omeprazole | 20 | $547 | $27 |
| Pantoprazole | 26 | $342 | $13 |
| Gavilyte-G | 20 | $282 | $14 |
| Promethazine | 14 | $128 | $9 |
2016: 3 drugs
| Harvoni | 14 | $441,134 | $31,510 |
| Xifaxan | 32 | $70,468 | $2,202 |
| Azathioprine | 11 | $452 | $41 |
2015: 6 drugs
| Harvoni | 36 | $1,125,140 | $31,254 |
| Xifaxan | 18 | $29,821 | $1,657 |
| Entecavir | 11 | $8,148 | $741 |
| Ursodiol | 21 | $5,314 | $253 |
| Spironolactone | 15 | $409 | $27 |
| Lactulose | 14 | $65 | $5 |
2014: 4 drugs
| Sovaldi | 13 | $368,793 | $28,369 |
| Olysio | 13 | $291,349 | $22,411 |
| Ursodiol | 12 | $2,132 | $178 |
| Lactulose | 14 | $354 | $25 |
Money from drug and device companies
$32,956 in 2025
| 2025 | 14 | 69 | $29,028 | $32,956 |
| 2024 | 7 | 35 | $15,804 | $18,450 |
| 2023 | 8 | 21 | None | $503 |
| 2022 | 2 | 3 | None | $154 |
| 2021 | 2 | 8 | None | $277 |
| 2020 | 1 | 1 | None | $110 |
| 2019 | 5 | 7 | None | $377 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Madrigal Pharmaceuticals | Rezdiffra | $32,078 | 39 payments
|
| Abbvie | Creon | $166 | 4 payments
|
| Janssen Biotech | Tremfya | $141 | 6 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $109 | 4 payments
|
| Boston Scientific | Exalt Model D | $99 | 1 payment
|
| Pfizer | Velsipity | $75 | 3 payments
|
See all 69 published payments
| QOL Medical | Meals · 2025-12-18 | Sucraid | $15 |
| Madrigal Pharmaceuticals | Consulting · 2025-12-15 | None | $968 |
| Abbvie | Meals · 2025-12-09 | Creon | $90 |
| Ardelyx | Meals · 2025-12-09 | Ibsrela | $26 |
| Novo Nordisk | Meals · 2025-12-05 | Wegovy | $29 |
| Pfizer | Meals · 2025-12-05 | Velsipity | $30 |
| Aimmune Therapeutics | Meals · 2025-11-17 | Zenpep | $32 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-11-05 | Rezdiffra | $3,548 |
| Madrigal Pharmaceuticals | Travel · 2025-11-05 | Rezdiffra | $18 |
| Madrigal Pharmaceuticals | Meals · 2025-11-05 | Rezdiffra | $118 |
| Pfizer | Meals · 2025-11-04 | Velsipity | $27 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-10-30 | Xifaxan | $20 |
| Madrigal Pharmaceuticals | Meals · 2025-10-27 | Rezdiffra | $42 |
| Boston Scientific | Meals · 2025-10-26 | Exalt Model D | $99 |
| Braintree Laboratories | Meals · 2025-10-21 | Sutab | $25 |
| Madrigal Pharmaceuticals | Meals · 2025-10-15 | Rezdiffra | $48 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-10-15 | Rezdiffra | $3,548 |
| QOL Medical | Meals · 2025-10-14 | Sucraid | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-14 | Entyvio | $24 |
| Janssen Biotech | Meals · 2025-10-07 | Tremfya | $28 |
| Madrigal Pharmaceuticals | Meals · 2025-09-30 | Rezdiffra | $49 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-09-30 | Rezdiffra | $3,548 |
| Madrigal Pharmaceuticals | Travel · 2025-09-30 | Rezdiffra | $7 |
| Lilly USA | Meals · 2025-09-16 | Omvoh | $19 |
| Janssen Biotech | Meals · 2025-09-09 | Tremfya | $23 |
| Madrigal Pharmaceuticals | Meals · 2025-09-09 | Rezdiffra | $28 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-08 | Entyvio | $26 |
| Janssen Biotech | Meals · 2025-07-26 | Tremfya | $25 |
| Madrigal Pharmaceuticals | Meals · 2025-07-19 | Rezdiffra | $70 |
| Madrigal Pharmaceuticals | Meals · 2025-07-19 | Rezdiffra | $38 |
| Madrigal Pharmaceuticals | Meals · 2025-07-19 | Rezdiffra | $95 |
| Madrigal Pharmaceuticals | Meals · 2025-07-19 | Rezdiffra | $57 |
| Madrigal Pharmaceuticals | Meals · 2025-07-19 | Rezdiffra | $61 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-07-18 | Rezdiffra | $4,838 |
| Madrigal Pharmaceuticals | Meals · 2025-07-18 | Rezdiffra | $15 |
| Madrigal Pharmaceuticals | Travel · 2025-07-18 | Rezdiffra | $36 |
| Madrigal Pharmaceuticals | Travel · 2025-07-18 | Rezdiffra | $337 |
| Madrigal Pharmaceuticals | Travel · 2025-07-18 | Rezdiffra | $244 |
| Madrigal Pharmaceuticals | Travel · 2025-07-18 | Rezdiffra | $169 |
| Madrigal Pharmaceuticals | Meals · 2025-07-18 | Rezdiffra | $196 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-27 | Entyvio | $39 |
| Janssen Biotech | Meals · 2025-06-24 | Tremfya | $30 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-06-12 | Rezdiffra | $3,548 |
| Madrigal Pharmaceuticals | Meals · 2025-06-12 | Rezdiffra | $102 |
| Madrigal Pharmaceuticals | Travel · 2025-06-12 | Rezdiffra | $71 |
| Madrigal Pharmaceuticals | Meals · 2025-06-12 | Rezdiffra | $65 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-06-10 | Xifaxan | $24 |
| Celltrion USA | Meals · 2025-06-10 | Vegzelma | $19 |
| Janssen Biotech | Meals · 2025-06-03 | Tremfya | $12 |
| Madrigal Pharmaceuticals | Meals · 2025-06-02 | Rezdiffra | $27 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-05-05 | Rezdiffra | $1,613 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-05-05 | Rezdiffra | $3,870 |
| Madrigal Pharmaceuticals | Travel · 2025-05-05 | Rezdiffra | $56 |
| Madrigal Pharmaceuticals | Travel · 2025-05-05 | Rezdiffra | $529 |
| Madrigal Pharmaceuticals | Travel · 2025-05-05 | Rezdiffra | $242 |
| Novo Nordisk | Meals · 2025-05-04 | None | $34 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-04-21 | Xifaxan | $20 |
| Pfizer | Meals · 2025-04-18 | Xeljanz | $18 |
| Janssen Biotech | Meals · 2025-04-11 | Tremfya | $23 |
| Madrigal Pharmaceuticals | Meals · 2025-04-08 | Rezdiffra | $18 |
| Abbvie | Meals · 2025-03-26 | Linzess | $16 |
| Madrigal Pharmaceuticals | Meals · 2025-03-15 | Rezdiffra | $63 |
| Madrigal Pharmaceuticals | Meals · 2025-03-12 | Rezdiffra | $38 |
| Madrigal Pharmaceuticals | Meals · 2025-03-12 | Rezdiffra | $105 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-03-12 | Rezdiffra | $3,548 |
| Madrigal Pharmaceuticals | Travel · 2025-03-12 | Rezdiffra | $108 |
| Abbvie | Meals · 2025-03-04 | Rinvoq | $29 |
| Abbvie | Meals · 2025-02-18 | Skyrizi | $31 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-04 | Entyvio | $20 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $18,450
| Madrigal Pharmaceuticals | Rezdiffra | $18,149 | 22 payments
|
| QOL Medical | Sucraid | $100 | 5 payments
|
| Janssen Biotech | Stelara | $90 | 3 payments
|
| Abbvie | Linzess | $40 | 2 payments
|
| Lilly USA | Omvoh | $30 | 1 payment
|
| Pfizer | Xeljanz | $24 | 1 payment
|
| Celgene | Zeposia | $16 | 1 payment
|
2023: $503
| Janssen Biotech | Stelara | $89 | 4 payments
|
| Genzyme | Dupixent | $88 | 4 payments
|
| Medtronic | Gi Genius | $81 | 1 payment
|
| AbbVie | Rinvoq | $64 | 3 payments
|
| QOL Medical | Sucraid | $61 | 3 payments
|
| Intercept Pharmaceuticals | Ocaliva | $58 | 3 payments
|
| Ferring Pharmaceuticals | Rebyota | $43 | 2 payments
|
| Exact Sciences | None | $18 | 1 payment
|
2022: $154
| Abbvie | Creon | $131 | 2 payments
|
| Janssen Biotech | Stelara | $23 | 1 payment
|
2021: $277
| AbbVie | Humira | $245 | 7 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $32 | 1 payment
|
2020: $110
| Cook Medical | Cook Medical Hemostasis | $110 | 1 payment
|
2019: $377
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $220 | 2 payments
|
| Dova Pharmaceuticals | Doptelet | $109 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Motegrity | $21 | 1 payment
|
| Allergan | Linzess | $14 | 1 payment
|
| Daiichi Sankyo | Injectafer | $13 | 1 payment
|
Professional record
- NPI
- 1285998609
- Licence
- CA 989517, CA A133210California A133210: Current · expires 2026-11-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X); Federal specialty code 207RI0008X (207RI0008X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2012-06-29
- NPI last updated
- 2021-01-29
- NPI record certified
- 2021-01-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 530 S Jackson St, Louisville, KY, 40202 · 12 Camino Encinas, Orinda, CA, 94563